What is this medicine used for?
FDA-approved uses
- Attention-deficit/hyperactivity disorder (ADHD) — Adults and pediatric patients aged 6 years and older. ADHD in adults and pediatric patients aged 6 years and older.Extended-release oral capsules (Qelbree).
What should I expect?
Benefit is evaluated over several weeks as the prescribed dose is adjusted. Attention, impulsivity and functioning may change gradually; a single good or difficult day does not establish the overall response.
Sleepiness, appetite changes or trouble sleeping can appear during treatment. Keep follow-up for mood, pulse, blood pressure and benefit; report worsening mood or suicidal thoughts immediately.
How do I take it safely?
Take once daily with or without food. Swallow whole or sprinkle the entire capsule contents on a teaspoonful or tablespoonful of applesauce or pudding; do not chew. Use pudding within 15 minutes or applesauce within two hours, and do not store the mixture.
Monitor mood, sleep, appetite, weight, pulse and blood pressure. Tell the clinician about personal or family bipolar disorder, depression or suicide-related symptoms. Severe kidney impairment requires lower dosing.
Do not combine with an MAO inhibitor or take within 14 days after stopping one. Some medicines broken down by the CYP1A2 enzyme must not be combined with Qelbree. A pharmacist should check every prescription, nonprescription product and supplement.
Take a missed dose when remembered unless the next is near; otherwise skip it. Never double. Discuss stopping or changing treatment with the prescriber.
If pregnancy occurs, contact the prescriber promptly: the label advises discontinuation unless benefits outweigh potential maternal risk. Human pregnancy and infant-effect data remain limited; discuss breastfeeding.
What side effects should I know about?
- Sleepiness or insomnia, tiredness, headache, nausea or reduced appetite.
- Pediatric vomiting/irritability or adult dry mouth/constipation may occur.
Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.
Looking for more detailed information?
The official medicine information lists more side effects, safety advice and product instructions.
- View FDA Prescribing Information (PDF) (opens in a new tab)Qelbree: prescribing information (revised January 2025; date shown is DailyMed record update)
Which warning signs need help?
- FDA boxed warningFDA boxed warningAn FDA boxed warning is a prominently displayed warning in US prescribing information about especially serious risks, which may include death or serious injury. It is sometimes called a black-box warning.It highlights information that needs particular attention when deciding whether and how to use a medicine. A boxed warning does not mean the medicine is banned or that everyone will experience the harm. Read the medicine-specific warning and discuss it with your prescriber.: higher rates of suicidal thoughts and behaviors were reported with Qelbree than placebo in clinical studies. All treated patients need close monitoring for new or worsening suicidal thoughts, mood or behavior changes, especially during the first few months and after dose changes. New suicidal thinking, extreme agitation or unusual behavior requires immediate contact with a clinician; imminent danger requires emergency help.
- Contact the prescriber promptly for unusually high energy, very little need for sleep or risky behavior; these can be signs of mania.
- Severe headache, chest symptoms or a markedly abnormal pulse or blood pressure needs urgent assessment.
- Get emergency help for trouble breathing, swelling of the tongue or throat, collapse, a seizure or inability to wake. Suspected overdose needs immediate poison-center or emergency advice; do not wait for symptoms.
What else should I know to stay safe?
- Do not combine with an MAO inhibitor or start within 14 days after stopping one. Qelbree can dangerously raise levels of certain other medicines; have every medicine and supplement checked.
- Monitor mood, sleep, appetite, weight, pulse and blood pressure, including after dose changes. Review personal or family bipolar disorder, depression or suicidal behavior. Severe kidney impairment requires a different dose plan.
- Contact the prescriber promptly if pregnancy occurs: the label advises discontinuation unless benefits outweigh potential maternal risk. Discuss breastfeeding because infant-effect data remain limited; plan other treatment changes with the prescriber.
Urgent help and crisis support · Emergency & Crisis Resources (US)
What can help day to day?
- “Nonstimulant” does not mean blood pressure will fall. Qelbree can raise both pulse and blood pressure.
- The capsule can be opened for people who cannot swallow it, but the mixture has specific food and timing instructions.
- Interaction checking is particularly important: Qelbree can increase levels of other medicines, even when those medicines are not used for ADHD.
How does it work?
Viloxazine changes how nerve cells handle norepinephrine, a chemical messenger also called noradrenaline. It slows the messenger’s return into cells, leaving more available between them. Researchers also describe an effect at a serotonin receiving site, but the full connection between these actions and improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms remains uncertain.
How was this medicine developed?
The FDA approved Qelbree for pediatric ADHD in 2021 and expanded the indication to adults in 2022. Its current US approval concerns the extended-release ADHD product, not a general approval for depression.
How do I say the name?
Viloxazine: vye-LOX-uh-zeen. Capital letters show the stressed syllable.
Sources and References
Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.
- Qelbree: prescribing information (revised January 2025; date shown is DailyMed record update)
- Qelbree: FDA approval and adult-indication history
- Viloxazine: patient medicine information
- Qelbree: FDA prescribing information, January 2025
- Qelbree: Package Insert / Prescribing Information / MOA
- Intuniv: current guanfacine ER label
- Viloxazine: verified parent compound, PubChem CID 5666
- Frequently Asked Questions about Labeling for Prescription Medicines | FDA
Giving medicine safely to children: family guide (PDF, 3 pages)

